Univest
Univest
  • Markets

3 Corn Starch Processor, Formulations Maker and Gold Jewellery Chain Stocks With a Strong Future Roadmap: Gujarat Ambuja Exports, Strides Pharma Science and Kalyan Jewellers India

  • November 18, 2026
  • Posted by: Ankit Jaiswal
  • Category: Best Stocks
No Comments
3 Corn Starch Processor, Formulations Maker and Gold Jewellery Chain Stocks With a Strong Future Roadmap: Gujarat Ambuja Exports, Strides Pharma Science and Kalyan Jewellers India

Gujarat Ambuja Exports, Strides Pharma Science and Kalyan Jewellers India: ROE of 14.2% to 21.4% and FY22 to FY26 revenue CAGR of 5.4% to 34.9%. Prices as of 17 Nov 2026.

Quick Answer

The three maize starch, generic drug and jewellery stocks to watch are Gujarat Ambuja Exports, Strides Pharma Science and Kalyan Jewellers India. Their return on equity ranges from 14.2% to 21.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.4% to 34.9%. Kalyan Jewellers India leads on both return on equity at 21.4% and revenue growth at 34.9% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.

Maize starch, generic drug and jewellery stocks give investors a way to track businesses that sit close to everyday demand in India. Gujarat Ambuja Exports, Strides Pharma Science and Kalyan Jewellers India cover an agro processing company, a generic medicines maker and a jewellery retailer.

This list covers three maize starch, generic drug and jewellery stocks with complete current figures: Gujarat Ambuja Exports, Strides Pharma Science and Kalyan Jewellers India. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Maize Starch, Generic Drug and Jewellery Stocks?
  • Maize Starch, Generic Drug and Jewellery Stocks at a Glance
  • Why Do Maize Starch, Generic Drug and Jewellery Stocks Have a Strong Roadmap in India?
  • Why Gujarat Ambuja Exports Features Among These Maize Starch, Generic Drug and Jewellery Stocks
  • Why Strides Pharma Science Features Among These Maize Starch, Generic Drug and Jewellery Stocks
  • Why Kalyan Jewellers India Features Among These Maize Starch, Generic Drug and Jewellery Stocks
  • Gujarat Ambuja Exports vs Strides Pharma Science vs Kalyan Jewellers India on Key Financials
  • Key Risks to Check Before Investing in Maize Starch, Generic Drug and Jewellery Stocks
  • Final Thoughts on Maize Starch, Generic Drug and Jewellery Stocks
    • What are maize starch, generic drug and jewellery stocks?
    • Which maize starch, generic drug and jewellery stocks are covered in this list?
    • Why do maize starch, generic drug and jewellery stocks have a strong future roadmap in India?
    • How has Gujarat Ambuja Exports performed financially?
    • How has Strides Pharma Science performed financially?
    • How has Kalyan Jewellers India performed financially?
    • What risks should investors check before buying maize starch, generic drug and jewellery stocks?
    • Is this list of maize starch, generic drug and jewellery stocks investment advice?

What Are Maize Starch, Generic Drug and Jewellery Stocks?

Maize starch, generic drug and jewellery stocks are listed companies that process maize into starch and edible products, make generic medicines for India and regulated markets, and sell gold and diamond jewellery through a large store network. Their earnings depend on agro commodity demand, medicine orders and jewellery demand.

Maize Starch, Generic Drug and Jewellery Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Gujarat Ambuja Exports 144.85 6,603 13.0 32.8 14.2 0.13
Strides Pharma Science 982.1 9,491 15.0 36.0 17.9 0.57
Kalyan Jewellers India 682.75 52,898 36.9 44.3 21.4 0.97

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing maize starch, generic drug and jewellery stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Maize Starch, Generic Drug and Jewellery Stocks Have a Strong Roadmap in India?

Maize starch, generic drug and jewellery stocks have a strong roadmap in India because steady demand for processed agro products, steady demand for medicines and strong jewellery buying in festivals and weddings keep widening the market for these companies.

  • Agro processing. Food makers need starch and oils.
  • Generic medicines. Patients need affordable treatment.
  • Jewellery. Families buy gold for weddings and festivals.

Why Gujarat Ambuja Exports Features Among These Maize Starch, Generic Drug and Jewellery Stocks

Among the maize starch, generic drug and jewellery stocks on this list, Gujarat Ambuja Exports is an Ahmedabad-based agro-processing company that makes maize-based products such as starch and derivatives, edible oils and cotton yarn, along with wind power.

The company has a return on equity of 14.2%, a debt to equity ratio of 0.13 and a market capitalisation of Rs 6,603 crore. The stock trades at a P/E of 13.0, below the industry P/E of 32.8.

Revenue rose from Rs 4,724 crore in FY22 to Rs 5,836 crore in FY26, a compound annual growth rate of 5.4%. Net profit grew from Rs 249 crore in FY25 to Rs 304 crore in FY26, a rise of 22.1%.

Roadmap: The company is expanding its maize processing and value-added starch products that serve food, pharma and paper customers. A mix of agro and power activities widens its sources of revenue.

What to watch: Follow capacity expansion, crop prices and demand from food and industrial customers.

Why Strides Pharma Science Features Among These Maize Starch, Generic Drug and Jewellery Stocks

Among the agro processing, pharma maker and gold retail shares on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.

Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%.

In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.

Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

What to watch: Track new US launches and the pace of price erosion in generic categories.

Why Kalyan Jewellers India Features Among These Maize Starch, Generic Drug and Jewellery Stocks

Among the three companies on this list, Kalyan Jewellers India is a large jewellery retailer with showrooms across India and the Middle East, selling gold, diamond and studded jewellery under the Kalyan and Candere brands.

In the June 2026 quarter, revenue grew 45.5% year on year to Rs 10,645 crore, while net profit rose 32.0% to Rs 349 crore. Revenue rose from Rs 10,856 crore in FY22 to Rs 35,951 crore in FY26, a compound annual growth rate of 34.9%.

Net profit grew from Rs 224 crore in FY22 to Rs 1,350 crore in FY26, which works out to a compound annual growth rate of 56.7%. The company has a return on equity of 21.4%, a debt to equity ratio of 0.97 and a market capitalisation of Rs 52,898 crore. The stock trades at a P/E of 36.9, below the industry P/E of 44.3.

Roadmap: The company is opening showrooms in newer cities and growing its online jewellery arm. Strong brand recall and a franchise-led expansion model help it enter new regions at lower capital needs.

What to watch: Track same-store sales, new showroom additions and gold price movements.

Gujarat Ambuja Exports vs Strides Pharma Science vs Kalyan Jewellers India on Key Financials

The table below sets the three maize starch, generic drug and jewellery stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Gujarat Ambuja Exports 4,724 5,836 5.4% 304 5.2%
Strides Pharma Science 3,202 5,009 11.8% 575 11.5%
Kalyan Jewellers India 10,856 35,951 34.9% 1,350 3.8%

Kalyan Jewellers India posts the highest return on equity in this group at 21.4%. Kalyan Jewellers India combines the largest FY26 revenue at Rs 35,951 crore with the fastest revenue growth, a 34.9% compound annual rate. A useful habit with maize starch, generic drug and jewellery stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Maize Starch, Generic Drug and Jewellery Stocks

Every theme carries risks that deserve a check before any decision. For these maize starch, generic drug and jewellery stocks, the main points are: Long-term agro processing, pharma maker and gold retail shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Commodity prices. Selling prices follow global and domestic markets.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Pricing pressure. Generic prices can change by market.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter maize starch, generic drug and jewellery stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Maize Starch, Generic Drug and Jewellery Stocks

Maize starch, generic drug and jewellery stocks work best when investors track growth, valuation and return on equity side by side. Gujarat Ambuja Exports, Strides Pharma Science and Kalyan Jewellers India each have a clear plan to grow. Based on the 17 November 2026 close, Gujarat Ambuja Exports trades at Rs 144.85, Strides Pharma Science at Rs 982.1 and Kalyan Jewellers India at Rs 682.75. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these maize starch, generic drug and jewellery stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track maize starch, generic drug and jewellery stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are maize starch, generic drug and jewellery stocks?

Ans. Maize starch, generic drug and jewellery stocks are listed companies that process maize into starch and edible products, make generic medicines for India and regulated markets, and sell gold and diamond jewellery through a large store network. Their earnings depend on agro commodity demand, medicine orders and jewellery demand. This list looks at three of them, Gujarat Ambuja Exports, Strides Pharma Science and Kalyan Jewellers India, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.

Which maize starch, generic drug and jewellery stocks are covered in this list?

Ans. This list covers Gujarat Ambuja Exports, Strides Pharma Science and Kalyan Jewellers India. Based on the 17 November 2026 close, Gujarat Ambuja Exports traded at Rs 144.85, Strides Pharma Science at Rs 982.1 and Kalyan Jewellers India at Rs 682.75. Their return on equity ranges from 14.2% to 21.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.4% to 34.9%.

Why do maize starch, generic drug and jewellery stocks have a strong future roadmap in India?

Ans. Maize starch, generic drug and jewellery stocks have a strong roadmap in India because steady demand for processed agro products, steady demand for medicines and strong jewellery buying in festivals and weddings keep widening the market for these companies. The main drivers are as follows. Agro processing. Food makers need starch and oils. Generic medicines. Patients need affordable treatment. Jewellery. Families buy gold for weddings and festivals. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Gujarat Ambuja Exports performed financially?

Ans. Revenue rose from Rs 4,724 crore in FY22 to Rs 5,836 crore in FY26, a compound annual growth rate of 5.4%. Net profit grew from Rs 249 crore in FY25 to Rs 304 crore in FY26, a rise of 22.1%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.13 and a market capitalisation of Rs 6,603 crore. The stock trades at a P/E of 13.0, below the industry P/E of 32.8. Looking ahead, the company is expanding its maize processing and value-added starch products that serve food, pharma and paper customers. A mix of agro and power activities widens its sources of revenue.

How has Strides Pharma Science performed financially?

Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

How has Kalyan Jewellers India performed financially?

Ans. Revenue rose from Rs 10,856 crore in FY22 to Rs 35,951 crore in FY26, a compound annual growth rate of 34.9%. Net profit grew from Rs 224 crore in FY22 to Rs 1,350 crore in FY26, which works out to a compound annual growth rate of 56.7%. In the June 2026 quarter, revenue grew 45.5% year on year to Rs 10,645 crore, while net profit rose 32.0% to Rs 349 crore. The company has a return on equity of 21.4%, a debt to equity ratio of 0.97 and a market capitalisation of Rs 52,898 crore. The stock trades at a P/E of 36.9, below the industry P/E of 44.3. Looking ahead, the company is opening showrooms in newer cities and growing its online jewellery arm. Strong brand recall and a franchise-led expansion model help it enter new regions at lower capital needs.

What risks should investors check before buying maize starch, generic drug and jewellery stocks?

Ans. Investors should check a few risks before buying maize starch, generic drug and jewellery stocks. Commodity prices. Selling prices follow global and domestic markets. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of maize starch, generic drug and jewellery stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



agro processing Best Stocks generic drug and jewellery stocks generic medicines and branded jewellery stocks Gujarat Ambuja Exports Kalyan Jewellers India maize products maize starch pharma maker and gold retail shares Strides Pharma Science
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply